Should we STOP immunosuppression for IgA nephropathy? Long-term outcomes from the STOP-IgAN trial.
other
Where this comes from
- Record sourced from PubMed, PMID 32998815.
- Also identified by DOI 10.1016/j.kint.2020.05.033.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The role of immunosuppression in the management of IgA nephropathy remains highly controversial. The Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial suggested that there was no benefit with the addition of immunosuppression to intensive supportive care, in terms of renal outcome. In this edition of Kidney International, Rauen et al. report long-term outcomes from the STOP-IgAN trial.
Medical subject headings
- Glomerulonephritis, IGA